Page 353 - Read Online

Paul J Cancer Metastasis Treat 2020;6:29 I http://dx.doi.org/10.20517/2394-4722.2020.63 Page 31 of 31

218. Yu H, Xia H, Tang Q, Xu H, Wei G, et al. Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and
promotes gastric cancer cell proliferation. Sci Rep 2017;7:40802.
219. Zhao CM, Hayakawa Y, Kodama Y, Muthupalani S, Westphalen CB, et al. Denervation suppresses gastric tumorigenesis. Sci Transl Med
2014;6:250ra115.
220. Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, et al. Nerve-cancer cell cross-talk: a novel promoter of tumor progression.
Cancer Res 2015;75:1777-81.
221. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010;85:838-54.
222. DeLellis RA, Xia L. Paraneoplastic endocrine syndromes: a review. Endocr Pathol 2003;14:303-17.
223. Castellone MD, Laukkanen MO, Teramoto H, Bellelli R, Ali G, et al. Cross talk between the bombesin neuropeptide receptor and Sonic
hedgehog pathways in small cell lung carcinoma. Oncogene 2015;34:1679-87.
224. Sherbet GV. Hormonal influences on cancer progression and prognosis. Vitam Horm 2005;71:147-200.
225. Mousa SA, Glinsky GV, Lin HY, Ashur-Fabian O, Hercbergs A, et al. Contributions of thyroid hormone to cancer metastasis.
Biomedicines 2018;6:89.
226. Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, et al. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res
2017;62.
227. Zaki NF, Sabri YM, Farouk O, Abdelfatah A, Spence DW, et al. Depressive symptoms, sleep profiles and serum melatonin levels in a
sample of breast cancer patients. Nat Sci Sleep 2020;12:135-49.
228. Yu B, Zanetti KA, Temprosa M, Albanes D, Appel N, et al. The consortium of metabolomics studies (COMETS): metabolomics in 47
prospective cohort studies. Am J Epidemiol 2019;188:991-1012.
229. Dean DC, Shen S, Hornicek FJ, Duan Z. From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma. Cancer
Metastasis Rev 2018;37:719-31.
230. Xiao S, Zhou L. Gastric cancer: metabolic and metabolomics perspectives (Review). Int J Oncol 2017;51:5-17.
231. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, et al. Molecular characterization and clinical relevance of metabolic expression
subtypes in human cancers. Cell Rep 2018;23:255-69.e4.
232. Cieslik M, Hoang SA, Baranova N, Chodaparambil S, Kumar M, et al. Epigenetic coordination of signaling pathways during the
epithelial-mesenchymal transition. Epigenetics Chromatin 2013;6:28.
233. Hong D, Messier TL, Tye CE, Dobson JR, Fritz AJ, et al. Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial
to mesenchymal transition. Oncotarget 2017;8:17610-27.
234. Vincent MD. Cancer: towards a general theory of the target: all successful cancer therapies, actual or potential, are reducible to either (or
both) of two fundamental strategies. Bioessays 2017;39.
235. Dai S, Wei D, Wu Z, Zhou X, Wei X, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for
colorectal cancer. Mol Ther 2008;16:782-90.
236. Que RS, Lin C, Ding GP, Wu ZR, Cao LP. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins
on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer. J Zhejiang Univ Sci B 2016;17:352-60.
237. Tauro BJ, Greening DW, Mathias RA, Mathivanan S, Ji H, et al. Two distinct populations of exosomes are released from LIM1863 colon
carcinoma cell-derived organoids. Mol Cell Proteomics 2013;12:587-98.
238. Kitano H. Biological robustness. Nat Rev Genet 2004;5:826-37.
239. Tyson JJ, Chen KC, Novak B. Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Curr
Opin Cell Biol 2003;15:221-31.
240. Chen JC, Alvarez MJ, Talos F, Dhruv H, Rieckhof GE, et al. Identification of causal genetic drivers of human disease through systems-
level analysis of regulatory networks. Cell 2014;159:402-14.
241. Archetti M, Pienta KJ. Cooperation among cancer cells: applying game theory to cancer. Nat Rev Cancer 2019;19:110-7.
242. Csermely P, Korcsmaros T. Cancer-related networks: a help to understand, predict and change malignant transformation. Semin Cancer
Biol 2013;23:209-12.
243. Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeno J, et al. Four-year survival with nivolumab in patients with
previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:1395-408.
244. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, et al. Five-year overall survival for patients with advanced nonsmall-cell
lung cancer treated with pembrolizumab: results from the phase I keynote-001 study. J Clin Oncol 2019;37:2518-27.
245. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, et al. Five-year survival with combined nivolumab and ipilimumab in
advanced melanoma. N Engl J Med 2019;381:1535-46.
246. Rosenzweig SA. Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res 2018;138:71-98.
247. Liu X, McMurphy T, Xiao R, Slater A, Huang W, et al. Hypothalamic gene transfer of BDNF inhibits breast cancer progression and
metastasis in middle age obese mice. Mol Ther 2014;22:1275-84.
248. Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, et al. Beta-adrenergic signaling in mice housed at standard temperatures
suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res 2017;77:5639-51.
249. Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, et al. Beta blocker use correlates with better overall survival in metastatic melanoma
patients and improves the efficacy of immunotherapies in mice. Oncoimmunology 2018;7:e1405205.
250. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart
failure. Eur Heart J 2014;35:932-41.
251. Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in
patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.